orteronel: Clinical Trials

6 completed. 6 Phase 2, 3 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	6	Completed 6
Phase 1	3	Completed 3

Follow orteronel: new trials by email Literature Review of orteronel trials Research Report on orteronel

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Orteronel - Metastatic Breast Cancer	Phase 2	Completed	SCRI Development Innovations, LLC	71	2014-03-01	2022-06-30
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer Orteronel, Orteronel Placebo, Prednisone - Prostate Cancer	Phase 1 / Phase 2	Completed	Millennium Pharmaceuticals, Inc.	137	2012-08-20	2018-03-20
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer Orteronel+Prednisone - Prostate Cancer	Phase 2	Completed	Millennium Pharmaceuticals, Inc.	50	2012-05-01	2016-06-01
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer TAK-700, Docetaxel, Prednisone - Prostate Cancer	Phase 1 / Phase 2	Completed	Millennium Pharmaceuticals, Inc.	38	2010-07-01	2019-07-30
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen TAK-700 - Prostate Cancer	Phase 2	Completed	Millennium Pharmaceuticals, Inc.	38	2010-05-01	2016-04-04
Safety Study of TAK-700 in Subjects With Prostate Cancer. TAK-700 - Prostatic Neoplasms	Phase 1 / Phase 2	Completed	Millennium Pharmaceuticals, Inc.	123	2008-04-01	2016-04-04

Conditions studied

Prostatic Neoplasms (5)  ·  Breast Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Millennium Pharmaceuticals, Inc. (5)  ·  SCRI Development Innovations, LLC (1)

Countries

United States (6)

Top investigators

Howard A Burris, III, MD (1)

Results publications

PMID 24965748